TAYSHA GENE THERAPIES INC

TSHA stock climbs 0.24% as investors track its $1.3B cap and gene‑therapy focus, offering a snapshot of market performance and future growth prospects.

See why Taysha Gene Therapies’ 4.31% rally is a high‑risk, high‑potential move in a volatile biotech market.